Miles Gerson
Ventures at Takeda Ventures
Miles Gerson
Ventures at Takeda Ventures
Cambridge, Massachusetts
Overview
Work Experience
Head, Takeda Ventures
2024 - Current
Takeda Ventures focuses on high-caliber, therapeutic, platform-based opportunities around the world. We invest in preclinical opportunities that complement Takeda’s pipeline and products. Our mission is to create strategic growth opportunities for Takeda by investing in and nurturing innovative, therapeutics companies in areas aligned with Takeda’s R&D foci which include; Oncology, Gastrointestinal, Inflammation and Neuroscience.
Executive Investment Director & Partner
2023 - 2024
Senior Investment Director & Partner
2021 - 2023
Partner
2020 - 2021
Board Member
2023
Board Member
2021
Board Member
2021
Audit Committee
Board Member
2022
Board Member
2021
Compensation Committee
Catamaran Bio is a biotechnology company that specializes in allogeneic immune cell therapies.
Raised $42,000,000.00 from Astellas Venture Management, Lightstone Ventures, SV Health Investors, Takeda Ventures and Sofinnova Partners.
Board Observer
2021
Carmine Therapeutics develops a novel type of gene therapy that utilizes extracellular vesicles produced in the laboratory.
Raised $3,400,000.00 from Huagai Capital, Cystic Fibrosis Foundation, Simcere Pharma and EVX Ventures.
Interim Head of GI Business Development
2021 - 2022
+ Served in a dual role capacity on an interim basis to support Takeda’s GI BD team while Takeda sourced a new team lead. + Managed BD transaction team for preclinical and clinical transactions for TAK’s GI Drug Development and Therapeutic Area Units + Led and guided negotiations of term sheets through to deal structuring for collaborations & licensing + Responsible for advising on strategic transactions and management of existing partnerships
Board Member
2021 - 2022
Senior Director, Business Development & Legal Affairs; Corporate Counsel and Compliance Officer
2016 - 2020
Formerly miRagen Therapeutics (NASDAQ:MGEN) + Member of MGEN’s Senior Leadership Team - Advising on corporate and commercial strategy + Head of Legal - Managed internal attorney team and multiple outside counsel internationally - Responsible for all legal and business term negotiations for all operational elements at MGEN - Supported Investor Relations and SEC compliance during and after MGEN’s reverse merger and listing on NASDAQ + Head of Business Development - Lead negotiator for term sheets, deal structuring for collaborations, and licensing - Responsible for strategic partnering, deal diligence, asset valuation, and market assessment - Lead for all partnering outreach across multiple therapeutic areas: oncology, cardiology, neurology, autoimmunity, dermatology, diabetes, fibrosis and ophthalmology
Viridian Therapeutics is a biotechnology company that offers treatments for patients suffering from diseases.
Raised $906,697,328.00 from Hercules Capital.